ClinicalTrials.gg
CompletedNCT00676091Updated Aug 8, 2011Results posted

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in Brazil

A Phase 3 interventional study of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) and 7-Valent Pneumococcal Conjugate Vaccine (7vPnc) in Vaccines, Pneumococcal Conjugate Vaccine, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 4 sites in Brazil. Open to participants aged 28 Days to 54 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-08-08.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
354
Allocation
Randomized
Ages
28 Days to 54 Days
Sex
All
01

Study summary

The purpose of this study will be to analyze 13-valent pneumococcal vaccine given to healthy infants in Brazil for safety and tolerability, and to determine the immune response to the vaccines.

02

Conditions studied

  • Vaccines, Pneumococcal Conjugate Vaccine

Keywords

  • Pneumococcal conjugate vaccine
03

In context

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.

First submitted before Wyeth became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 54 Days
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy 1 month old infants
  • Available for the duration of the study and reachable by telephone
  • Able to complete two blood drawing procedures during the study

Exclusion criteria

Exclusion criteria:

  • Previous vaccination, or history of allergic reaction to vaccine or vaccine components
  • Bleeding disorder, immune deficiency or significant chronic or congenital disease
  • Previous receipt of blood products or immune globulin
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
354 participants (actual)

Study arms

  • Experimental
    13vPnC

    13-valent pneumococcal conjugate vaccine (13vPnC) 0.5 milliliter (mL) dose administered intramuscularly (IM) at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).

    Biological: 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

  • Active comparator
    7vPnC

    7-valent pneumococcal conjugate vaccine (7vPnC) 0.5 mL dose administered IM at 2, 4, and 6 months of age (infant series) and 12 months of age (toddler dose).

    Biological: 7-Valent Pneumococcal Conjugate Vaccine (7vPnc)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: 1 Month after the infant series (7 Months of age)

  2. Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

    Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.

    Time frame: 1 month after the infant series (7 months of age)

Secondary outcomes

  1. Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

    Time frame: 1 month after the toddler dose (13 months of age)

  2. Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

    Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.

    Time frame: 1 month after the toddler dose (13 months of age)

Other outcomes

  1. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)

    Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 1 (2 months of age)

  2. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)

    Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 2 (4 months of age)

  3. Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)

    Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 3 (6 months of age)

  4. Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

    Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

    Time frame: Within 4 days after toddler dose (12 months of age)

  5. Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)

    Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 1 (2 months of age)

  6. Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)

    Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 2 (4 months of age)

  7. Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)

    Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after dose 3 (6 months of age)

  8. Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)

    Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

    Time frame: Within 4 days after toddler dose (12 months of age)

07

Results

Posted Oct 15, 2010

Participant flow

Infant Series
Participant flow — Infant Series
Milestone13vPnC7vPnC
Started177177
Vaccinated dose 1163162
Vaccinated dose 2159162
Vaccinated dose 3158161
Completed157159
Not completed2018
Withdrew: Parent or legal guardian request108
Withdrew: Protocol violation63
Withdrew: Adverse event23
Withdrew: Failed to return13
Withdrew: Lost to follow-up10
Withdrew: Died prior to receiving 7vpnc01
After Infant Series
Participant flow — After Infant Series
Milestone13vPnC7vPnC
Started157159
Completed156156
Not completed13
Withdrew: Adverse event01
Withdrew: Protocol violation01
Withdrew: Failed to return11
Toddler Dose
Participant flow — Toddler Dose
Milestone13vPnC7vPnC
Started156156
Completed153156
Not completed30
Withdrew: Failed to return20
Withdrew: Parent or legal guardian request10

Outcome measures

PrimaryPercentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
1 Month after the infant series (7 Months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Micrograms Per Milliliter (Mcg/mL) in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
percentage of participants13vPnC7vPnC
Common serotypes - serotype 4100.0 (97.7 to 100.0)100.0 (97.7 to 100.0)
Common serotypes - serotype 6B96.8 (92.7 to 99.0)95.6 (91.1 to 98.2)
Common serotypes - serotype 9V98.7 (95.4 to 99.8)100.0 (97.7 to 100.0)
Common serotypes - serotype 1498.1 (94.5 to 99.6)97.5 (93.6 to 99.3)
Common serotypes - serotype 18C97.4 (93.6 to 99.3)98.1 (94.5 to 99.6)
Common serotypes - serotype 19F94.2 (89.3 to 97.3)98.7 (95.5 to 99.8)
Common serotypes - serotype 23F96.8 (92.7 to 99.0)93.0 (87.8 to 96.5)
Additional serotypes - serotype 199.4 (96.5 to 100.0)2.5 (0.7 to 6.4)
Additional serotypes - serotype 387.1 (80.8 to 91.9)4.4 (1.8 to 8.9)
Additional serotypes - serotype 598.7 (95.4 to 99.8)38.2 (30.4 to 46.4)
Additional serotypes - serotype 6A97.4 (93.6 to 99.3)52.6 (44.4 to 60.6)
Additional serotypes - serotype 7F100.0 (97.7 to 100.0)1.3 (0.2 to 4.6)
Additional serotypes - serotype 19A99.4 (96.5 to 100.0)98.7 (95.4 to 99.8)
PrimaryPercentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series

Percentage of participants achieving predefined antibody threshold ≥5 enzyme-linked immunosorbent assay (ELISA) units per mL (EU/mL) along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.

Time frame:
1 month after the infant series (7 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥5 Enzyme-linked Immunosorbent Assay (ELISA) Units Per mL (EU/mL) for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series
percentage of participants13vPnC7vPnC
PT ≥5 EU/mL35.9 (28.4 to 44.0)32.3 (25.1 to 40.2)
FHA ≥5 EU/mL70.1 (62.2 to 77.2)71.5 (63.8 to 78.4)
PRN ≥5 EU/mL93.5 (88.5 to 96.9)96.2 (91.9 to 98.6)
SecondaryPercentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Serotype Specific IgG Antibody Concentration ≥0.35 Mcg/mL in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
percentage of participants13vPnC7vPnC
Common serotypes - serotype 4100.0 (97.6 to 100.0)100.0 (97.6 to 100.0)
Common serotypes - serotype 6B97.4 (93.4 to 99.3)98.7 (95.3 to 99.8)
Common serotypes - serotype 9V100.0 (97.6 to 100.0)100.0 (97.6 to 100.0)
Common serotypes - serotype 14100.0 (97.6 to 100.0)99.3 (96.4 to 100.0)
Common serotypes - serotype 18C99.3 (96.4 to 100.0)100.0 (97.6 to 100.0)
Common serotypes - serotype 19F99.3 (96.4 to 100.0)98.7 (95.3 to 99.8)
Common serotypes - serotype 23F98.7 (95.3 to 99.8)99.3 (96.4 to 100.0)
Additional serotypes - serotype 1100.0 (97.6 to 100.0)2.7 (0.7 to 6.7)
Additional serotypes - serotype 392.1 (86.5 to 95.8)7.5 (3.8 to 13.0)
Additional serotypes - serotype 5100.0 (97.6 to 100.0)72.1 (63.9 to 79.4)
Additional serotypes - serotype 6A100.0 (97.6 to 100.0)92.1 (86.5 to 95.8)
Additional serotypes - serotype 7F100.0 (97.6 to 100.0)4.2 (1.5 to 8.8)
Additional serotypes - serotype 19A100.0 (97.6 to 100.0)100.0 (97.6 to 100.0)
SecondaryPercentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose

Percentage of participants achieving predefined antibody threshold ≥5 EU/mL along with the corresponding 95% CI for concomitant antigen pertussis (pertussis toxoid \[PT\], filamentous hemagglutinin \[FHA\], and pertactin \[PRN\]) are presented.

Time frame:
1 month after the toddler dose (13 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Antibody Level ≥5 EU/mL for Pertussis in the 13vPnC Group Relative to 7vPnC Group 1 Month After the Toddler Dose
percentage of participants13vPnC7vPnC
PT ≥5 EU/mL50.7 (42.4 to 58.9)49.3 (41.1 to 57.6)
FHA ≥5 EU/mL91.4 (85.8 to 95.4)88.8 (82.7 to 93.3)
PRN ≥5 EU/mL99.3 (96.4 to 100.0)98.7 (95.3 to 99.8)
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)

Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 1 (2 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 1 (2 Months of Age)
percentage of participants13vPnC7vPnC
Tenderness: Any60.059.4
Tenderness: Significant14.012.8
Swelling: Any13.915.0
Swelling: Mild10.313.6
Swelling: Moderate5.91.4
Swelling: Severe0.00.0
Redness: Any10.313.4
Redness: Mild8.811.4
Redness: Moderate2.92.1
Redness: Severe0.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)

Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 2 (4 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 2 (4 Months of Age)
percentage of participants13vPnC7vPnC
Tenderness: Any53.353.8
Tenderness: Significant9.411.9
Swelling: Any12.113.8
Swelling: Mild10.510.0
Swelling: Moderate2.43.9
Swelling: Severe0.00.0
Redness: Any9.312.4
Redness: Mild9.311.6
Redness: Moderate0.01.6
Redness: Severe0.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)

Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 3 (6 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Infant Series Dose 3 (6 Months of Age)
percentage of participants13vPnC7vPnC
Tenderness: Any48.147.4
Tenderness: Significant10.98.8
Swelling: Any14.69.7
Swelling: Mild12.29.7
Swelling: Moderate4.20.9
Swelling: Severe0.00.0
Redness: Any10.714.0
Redness: Mild10.713.3
Redness: Moderate0.80.9
Redness: Severe0.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)

Pre-specified local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Swelling and redness were scaled as Any (swelling or redness present); Mild (0.5 centimeters \[cm\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\> 7.0 cm). Participants may be represented in more than 1 category.

Time frame:
Within 4 days after toddler dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Local Reactions: Toddler Dose (12 Months of Age)
percentage of participants13vPnC7vPnC
Tenderness: Any64.353.2
Tenderness: Significant18.313.3
Swelling: Any11.510.5
Swelling: Mild8.18.7
Swelling: Moderate5.33.9
Swelling: Severe0.00.0
Redness: Any13.38.7
Redness: Mild12.47.8
Redness: Moderate0.91.0
Redness: Severe0.00.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)

Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 1 (2 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 1 (2 Months of Age)
percentage of participants13vPnC7vPnC
Fever ≥38 but ≤39 degrees C18.019.9
Fever >39 but ≤40 degrees C0.00.7
Fever >40 degrees C0.00.0
Decreased appetite26.628.0
Irritability80.377.9
Increased sleep56.652.4
Decreased sleep39.727.5
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)

Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 2 (4 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 2 (4 Months of Age)
percentage of participants13vPnC7vPnC
Fever ≥38 but ≤39 degrees C23.823.0
Fever >39 but ≤40 degrees C3.20.8
Fever >40 degrees C0.00.0
Decreased appetite33.829.6
Irritability80.479.2
Increased sleep32.838.7
Decreased sleep25.836.0
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)

Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after dose 3 (6 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events: Infant Series Dose 3 (6 Months of Age)
percentage of participants13vPnC7vPnC
Fever ≥38 but ≤39 degrees C22.622.4
Fever >39 but ≤40 degrees C4.23.5
Fever >40 degrees C0.80.9
Decreased appetite37.932.2
Irritability76.971.2
Increased sleep35.736.9
Decreased sleep27.634.1
Other pre-specifiedPercentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)

Pre-specified systemic events (any fever ≥ 38 degrees Celsius \[C\], decreased appetite, irritability, increased sleep, and decreased sleep) were reported using an electronic diary. Participants may be represented in more than 1 category.

Time frame:
Within 4 days after toddler dose (12 months of age)
Reported as:
Number · percentage of participants
Percentage of Participants Reporting Pre-specified Systemic Events: Toddler Dose (12 Months of Age)
percentage of participants13vPnC7vPnC
Fever ≥38 but ≤39 degrees C31.029.9
Fever >39 but ≤40 degrees C1.83.0
Fever >40 degrees C0.90.0
Decreased appetite33.339.0
Irritability67.268.8
Increased sleep30.824.1
Decreased sleep22.720.6

Adverse events

Collected over Baseline through 1 Month after last study vaccination (13 Months). Local reactions and systemic events assessed within 4 days of dose: Infant Series Dose 1=2 months of age; Dose 2=4 months of age; Dose 3=6 months of age; Toddler Dose=12 months of age.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Infant Series 13vPnC—10/163 (6.1%)140/163 (85.9%)
Infant Series 7vPnC—10/162 (6.2%)140/162 (86.4%)
After the Infant Series 13vPnC—10/163 (6.1%)18/163 (11%)
After the Infant Series 7vPnC—5/162 (3.1%)12/162 (7.4%)
Toddler Dose 13vPnC—2/155 (1.3%)84/155 (54.2%)
Toddler Dose 7vPnC—3/156 (1.9%)86/156 (55.1%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventInfant Series 13vPnCInfant Series 7vPnCAfter the Infant Series 13vPnCAfter the Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnC
Hypotonic-hyporesponsive episodeNervous system disorders1/1633/1620/1630/1620/1550/156
BronchopneumoniaInfections and infestations0/1630/1622/1632/1620/1552/156
BronchospasmRespiratory, thoracic and mediastinal disorders1/1630/1622/1631/1621/1552/156
Urinary tract infectionInfections and infestations0/1632/1620/1631/1620/1550/156
PneumoniaInfections and infestations1/1631/1622/1630/1621/1550/156
LaryngitisInfections and infestations0/1630/1620/1630/1620/1551/156
DehydrationMetabolism and nutrition disorders0/1631/1621/1630/1620/1551/156
Congenital hydrocephalusCongenital, familial and genetic disorders0/1630/1620/1631/1620/1550/156
Inguinal herniaGastrointestinal disorders1/1631/1620/1630/1620/1550/156
IntussusceptionGastrointestinal disorders0/1631/1620/1630/1620/1550/156
Most frequent other events
Showing 10 of 198
Most frequent other events
EventInfant Series 13vPnCInfant Series 7vPnCAfter the Infant Series 13vPnCAfter the Infant Series 7vPnCToddler Dose 13vPnCToddler Dose 7vPnC
IrritabilityGeneral disorders111/138122/154————
IrritabilityGeneral disorders122/152116/149——84/12586/125
IrritabilityGeneral disorders110/14399/139————
Tenderness (any)Skin and subcutaneous tissue disorders87/14592/155——81/12667/126
Increased sleepGeneral disorders81/14377/147——36/11726/108
Tenderness (any)Skin and subcutaneous tissue disorders72/13578/145————
Tenderness (any)Skin and subcutaneous tissue disorders63/13163/133————
Decreased sleepGeneral disorders56/14138/138——27/11922/107
Decreased appetiteGeneral disorders38/14340/143——39/11746/118
Increased sleepGeneral disorders41/12555/142————

Baseline characteristics

Age Continuous
Age Continuous(months)13vPnC7vPnCTotal
Mean2.2 ± 0.22.2 ± 0.22.2 ± 0.2
Sex: Female, Male
Sex: Female, Male(Participants)13vPnC7vPnCTotal
Female8976165
Male7486160
08

Study locations

4 sites
  • Curitiba, 80060-900, Brazil
  • Florianopolis, 88025-301, Brazil
  • Sau Paulo, 04020-060, Brazil
  • Sau Paulo, 04038-001, Brazil
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Sep 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2008
First posted
May 12, 2008
Start
Apr 2008
Primary completionActual
Sep 2009
CompletionActual
Sep 2009
Results first posted
Oct 15, 2010
Last update
Aug 8, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00676091
First posted
May 12, 2008
Start date
Apr 2008
Primary completion
Sep 2009
Completion
Sep 2009
Results posted
Oct 15, 2010
Last update
Aug 8, 2011

Study contacts

Medical Monitor
study director · Wyeth is now a wholly owned subsidiary of Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: 13-valent pneumococcal vaccine

Start the discussion